Core Insights - The LUMINA project aims to develop an advanced Minimal Residual Disease (MRD) detection platform for lung cancer, utilizing multi-omics biomarkers and AI technology to enhance early detection and treatment personalization [19][8][1] Group 1: Project Overview - The LUMINA project is a collaboration involving RenovaroCube, Flomics Biotech, Uppsala University, and Oncodia, focusing on improving lung cancer patient survival through innovative diagnostic solutions [2][13][1] - The platform targets the significant issue of lung cancer recurrence, with 60% of curatively treated patients experiencing relapse, highlighting the critical need for improved detection methods [1][19] Group 2: Technology and Methodology - The platform integrates liquid biopsies and multi-omics biomarker technology, representing a revolutionary approach to cancer diagnostics [8][19] - RenovaroCube's AI platform processes multi-omic molecular data to discover biomarkers essential for early cancer detection and treatment monitoring [16][3] Group 3: Market Context - Over 5.7 million lung cancer cases are treated or monitored globally each year, indicating a substantial market opportunity for the LUMINA project [1] - The project is supported by the Eurostars funding program, which facilitates international collaboration for innovative R&D projects, with over €250 million in expected public-private investment annually [7][13]
RenovaroCube Receives Approval of Lumina Project by the Eurostars Funding Program